Project Grant R01HL181868
Award Date 8/18/25
Completion Date 5/31/29
Dollars Obligated $715K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
- This federal Project Grant award of $730,764 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will fund research at Case Western Reserve University to define the effects of cardiac myosin binding protein C (cMyBP-C) missense variants on cardiac sarcomere molecular structure and function, and link these mechanisms to altered whole organ structure, function, and the development of hypertrophic cardiomyopathy (HCM). The project aims to improve...
- The federal Project Grant award of $741,112 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) is supporting research at The Ohio State University to investigate the impact of the adaptive immune system on cardiac electrophysiology. The research aims to elucidate the mechanisms by which heart failure-activated CD4+ T-cells contribute to cardiac dysfunction and arrhythmias. Key activities include assessing the contact-dependent alterations in...
- This $149,804 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research on the structural and functional features of the native cardiac sarcomere in hypertrophic cardiomyopathy (HCM). The project aims to directly observe the conformational changes in the beta-myosin motor protein caused by HCM-inducing mutations and the FDA-approved drug mavacamten, using advanced cryo-electron tomography...
- The Project Grant award of $713,421 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to understand the regulation of thin filament architecture by the actin-binding protein CAP2 and its role in the development of life-threatening muscle diseases such as dilated cardiomyopathy (DCM) and nemaline myopathy. The research aims to elucidate the mechanisms by which CAP2 mediates the exchange of actin isoforms within cardiac thin...
- This $776,791 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate the impact of sequence changes on key intrinsically disordered regions of cardiac troponin. The research aims to improve understanding of how changes in the sequence of troponin subunits affect the regulation of cardiac muscle contraction, which is critical for cardiac function and can lead to diseases like cardiomyopathy...
- The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $694,754 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The Washington University in Missouri. The 5-year grant, which commenced on August 1, 2025, will support research to investigate the fundamental molecular mechanisms driving the pathogenesis of key troponin cardiomyopathy mutations and their effects on cellular and tissue function. The...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $618,045 to the University of Arizona to conduct research on identifying new mechanisms and targets for treating diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The primary objectives are to: 1) fully characterize at the atomic level three specific functional domains of the cardiac thin filament linked to the...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research at the University of Vermont focused on investigating the impact of myosin-binding protein C (MyBP-C) on myosin mobility and proteostasis in the context of hypertrophic cardiomyopathy (HCM). The $713,511 award aims to advance the understanding of how reduced levels of MyBP-C, frequently caused by MYBPC3 gene mutations, disrupt...
- This federal Project Grant award of $639,621, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), supports research on the role of mitochondria in the communication between cardiomyocytes and fibroblasts in the heart. The research aims to understand how disruption of this mitochondrial cross-talk may contribute to cardiac fibrosis, with a focus on the impact of the PI3K-gamma signaling pathway. Key activities involve proteomic analysis of...
- The National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $167,400 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Dr. Joshua Meisner at the University of Michigan. The award aims to elucidate the mechanical and metabolic pathways underlying hypertrophic cardiomyopathy caused by truncating variants of the MYBPC3 gene, a leading cause of sudden cardiac death and heart failure, especially in children and adolescents....